Nishikori A, Nishimura MF, Nishimura Y, Yamada R, Haratake T, Ennishi D, Chijimatsu R, Ito T, Koga T, Ochi S, Kawahara Y, Ueta H, Takeda Y, Gonzalez MV, Fajgenbaum DC, Van Rhee F, Momose S, Sato Y. Distinct interleukin-6 production in IPL and TAFRO subtypes of idiopathic multicentric Castleman disease. Haematologica. 2026 May;111(5):1705-1715. doi: 10.3324/haematol.2025.288147. PMID: 40931874; PMCID: PMC13136834.
Acharya B, Hanafi M, Enemark L, Armstrong D, Saha D, Miah S, Frett B. Discovery of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRK/PTK6 inhibitors. European journal of medicinal chemistry. 2025 Dec;300:118145. doi: 10.1016/j.ejmech.2025.118145. PMID: 40967071; PMCID: PMC12574688.
Schinke C, Rodriguez-Otero P, van de Donk NWCJ, Lipe BC, Lavi N, Rasche L, Parekh S, Van Oekelen O, Vishwamitra D, Skerget S, Cortes-Selva D, Verona RI, Hilder BW, Masterson T, Campagna M, Khedkar S MBBS, MSPH, Renaud T, Tolbert J, Kane C, Gray K, Saber I, Heuck C, Chari A. Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1. Blood advances. 2025 Nov;9(22):5752-5762. doi: 10.1182/bloodadvances.2025016613. PMID: 40864183; PMCID: PMC12661299.
Shrestha A, Thanendrarajan S, Bag A, Dhakal B, Zangari M, Al-Hadidi S, van Rhee F, D’Souza A, Shah N, Shah MR, Mohan M, Schinke C. The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia. Blood advances. 2025 Oct;9(19):4806-4809. doi: 10.1182/bloodadvances.2025016695. PMID: 40674710; PMCID: PMC12494909.
Schinke CD, Rasche L, Ashby TC, Van Hemert RL, Thanendrarajan S, Al Hadidi S, Zangari M, Bailey C, Alapat DV MD, Shaughnessy JD Jr, Zhan F, Barlogie B, van Rhee F, Weinhold N. Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging. Blood advances. 2025 Sep;9(17):4368-4377. doi: 10.1182/bloodadvances.2025016510. PMID: 40590883; PMCID: PMC12447427.
Nishimura MF, Haratake T, Nishimura Y, Nishikori A, Sumiyoshi R, Ujiie H, Kawahara Y, Koga T, Ueki M, Laczko D, Oksenhendler E, Fajgenbaum DC, van Rhee F, Kawakami A, Sato Y. International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis. American journal of hematology. 2025 Sep;100(9):1502-1512. doi: 10.1002/ajh.27743. PMID: 40540535; PMCID: PMC12326216.
Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Siegel ER, Bailey C, Smith R, Panozzo SB, Zangari M, Tricot G, Shaughnessy JD Jr, Zhan F, Sawyer J, Barlogie B, van Rhee F. Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials. JAMA oncology. 2025 Aug;11(8):910-915. doi: 10.1001/jamaoncol.2025.1394. PMID: 40471585; PMCID: PMC12142471.
Haratake T, Nishimura MF, Nishikori A, Gonzalez MV, Ennishi D, Lai YC, Ochi S, Tsunoda M, Fajgenbaum DC, van Rhee F, Momose S, Sato Y. The Involvement of PI3K-Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease-Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified Subtypes. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2025 Aug;38(8):100782. doi: 10.1016/j.modpat.2025.100782. PMID: 40274066; PMCID: PMC12809888.
Grujicic J, Allen AR. Manganese Superoxide Dismutase: Structure, Function, and Implications in Human Disease. Antioxidants (Basel, Switzerland). 2025 Jul;14(7). doi: 10.3390/antiox14070848. PMID: 40722952; PMCID: PMC12291727.
Edmondson JL, Reed MR, Fil D, Heflin B, McKinnon A, Bauer MA, Morehead LC, Avaritt NL, Phillips M, Taverna SD, Tackett AJ, Koss B. EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma. iScience. 2025 Jun;28(6):112750. doi: 10.1016/j.isci.2025.112750. PMID: 40546964; PMCID: PMC12182326.
Li D, Li J, Johann DJ Jr, Butler D, Chen G, Foox J, Gong B, Jones W, Kreil DP, Kusko R, Łabaj PP, Lucas AB, Mason CE, Mozsary C, Novoradovskaya N, Pabón-Peña C, Pan B, Richmond TA, Maestro R, Ebrahim Sahraeian SM, Scherer A, Tilgner HU, Willey JC, Bushel PR, Xu J. Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations. NPJ precision oncology. 2025 Jun;9(1):182. doi: 10.1038/s41698-025-00993-8. PMID: 40514442; PMCID: PMC12166063.
Mohan Lal B, Alzubi M, Alrawabdeh J, Shaughnessy JD Jr, Zhan F, Siegel ER, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Al Hadidi S. Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma. Blood advances. 2025 May;9(9):2155-2158. doi: 10.1182/bloodadvances.2024015648. PMID: 39938011; PMCID: PMC12051553.
Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A, Balev M, Bhutani D, Shrestha A, Thanendrarajan S, Dhakal B, Zangari M, Trikannad A, Vellanki S, Al-Hadidi S, Lentzsch S, van Rhee F, Bag A, D’Souza A, Shah N, Chakraborty R, Shah MR, Schinke C. Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood cancer journal. 2025 Apr;15(1):74. doi: 10.1038/s41408-025-01282-0. PMID: 40268898; PMCID: PMC12018942.
Pierson SK, Brandstadter JD, Torigian D, Bagg A, Lechowicz MJ, Alapat D MD, Casper C, Chadburn A, Chandrakasan S, Dispenzieri A, Fosså A, Hoffmann C, Ide M, Kurzrock R, Mukherjee S, Nasta SD, Navarro JT, Noy A, Oksenhendler E, Sarmiento Bustamante M, Shyamsundar S, Streetly MJ, Wong RSM, Zhang L, Lim MS, Srkalovic G, van Rhee F, Fajgenbaum DC. Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry. Blood advances. 2025 Apr;9(8):1952-1965. doi: 10.1182/bloodadvances.2024014391. PMID: 39951615; PMCID: PMC12018988.
Srivastava S, Sekar G, Ojoawo A, Aggarwal A, Ferreira E, Uchikawa E, Yang M, Grace CR, Dey R, Lin YL, Guibao CD, Jayaraman S, Mukherjee S, Kossiakoff AA, Dong B, Myasnikov A, Moldoveanu T. Structural basis of BAK sequestration by MCL-1 in apoptosis. Molecular cell. 2025 Apr;85(8):1606-1623.e10. doi: 10.1016/j.molcel.2025.03.013. PMID: 40187349; PMCID: PMC12086701.
Otsuka M, Koga T, Sumiyoshi R, Fukui S, Kaneko Y, Shimizu T, Katsube A, Yano S, Masaki Y, Ide M, Yoshifuji H, Kitano M, Sato Y, Sawa N, Niiro H, Nakamura N, Fajgenbaum DC, van Rhee F, Kawakami A. Exploring the Clinical Diversity of Castleman Disease and TAFRO Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns. American journal of hematology. 2025 Apr;100(4):592-605. doi: 10.1002/ajh.27612. PMID: 39865257; PMCID: PMC11886485.
Watters CR, Barro O, Gabere M, Masuda MY, Elliott NM, Raupach EA, Ferdous KU, Tesfay MZ, Moaven O, Zhou Y, Barrett MT, Buetow KH, Nagalo BM, Borad MJ. Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma. Molecular therapy. Oncology. 2025 Mar;33(1):200937. doi: 10.1016/j.omton.2025.200937. PMID: 40123977; PMCID: PMC11930419.
Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Smith RT, Panozzo S, Alapat D MD, Tricot GJ, Shaughnessy JD Jr, Zhan F, Sawyer JR, Siegel ER, Barlogie B, van Rhee F, Zangari M. Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma. Blood advances. 2025 Feb;9(4):950-953. doi: 10.1182/bloodadvances.2024014889. PMID: 39786380; PMCID: PMC11934280.
Lekadir K, Frangi AF, Porras AR, Glocker B, Cintas C, Langlotz CP, Weicken E, Asselbergs FW, Prior F, Collins GS, Kaissis G, Tsakou G, Buvat I, Kalpathy-Cramer J, Mongan J, Schnabel JA, Kushibar K, Riklund K, Marias K, Amugongo LM, Fromont LA, Maier-Hein L, Cerdá-Alberich L, Martí-Bonmatí L, Cardoso MJ, Bobowicz M, Shabani M, Tsiknakis M, Zuluaga MA, Fritzsche MC, Camacho M, Linguraru MG, Wenzel M, De Bruijne M, Tolsgaard MG, Goisauf M, Cano Abadía M, Papanikolaou N, Lazrak N, Pujol O, Osuala R, Napel S, Colantonio S, Joshi S, Klein S, Aussó S, Rogers WA, Salahuddin Z, Starmans MPA. FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. BMJ (Clinical research ed.). 2025 Feb;388:e081554. doi: 10.1136/bmj-2024-081554. PMID: 39909534; PMCID: PMC11795397.
Rühl S, Li Z, Srivastava S, Mari L, Guy CS, Yang M, Moldoveanu T, Green DR. Inhibition of BAK-mediated apoptosis by the BH3-only protein BNIP5. Cell death and differentiation. 2025 Feb;32(2):320-336. doi: 10.1038/s41418-024-01386-3. PMID: 39406920; PMCID: PMC11803101.
Pal S, Bagchi AK, Henry DS, Landes RD, Mu S, Rhee SW, Rusch NJ, Stolarz AJ. Rhythmic Contractions of Lymph Vessels and Lymph Flow Are Disrupted in Hypertensive Rats. Hypertension (Dallas, Tex. : 1979). 2025 Jan;82(1):72-83. doi: 10.1161/HYPERTENSIONAHA.124.23194. PMID: 39502071; PMCID: PMC11654453.
Omolekan TO, Folahan JT, Tesfay MZ, Mohan H, Dutta O, Rahimian L, Ferdous KU, Ghavimi R, Cios A, Beng TK, Francis J, D’Auvergne O, Borad MJ, Kousoulas KG, DiGiuseppe S, Nagalo BM, Chamcheu JC. Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer’s defenses. Frontiers in immunology. 2025 Jan;16:1618751. doi: 10.3389/fimmu.2025.1618751. PMID: 40927720; PMCID: PMC12414947.
Tesfay MZ, Cios A, Ferdous KU, Shelton RS, Mustafa B, Simoes CC, Gokden M, Miousse IR, Krager KJ, Boerma M, Urbaniak A, Kunthur A, Obulareddy S, Eichhorn JM, Post SR, Chamcheu JC, Moaven O, Chabu CY, Duda DG, Conti M, Nardo B, Govindarajan R, Fernandez-Zapico ME, Roberts LR, Borad MJ, Cannon MJ, Basnakian AG, Nagalo BM. Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models. Frontiers in immunology. 2025 Jan;16:1679665. doi: 10.3389/fimmu.2025.1679665. PMID: 41142777; PMCID: PMC12546120.
Wang X, Sato AY, Marino S, Akel N, Boysen G, Basnakian AG, Bellido TM, Li HY. Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss. Journal of medicinal chemistry. 2024 Nov;67(22):20708-20720. doi: 10.1021/acs.jmedchem.4c02539. PMID: 39540576; PMCID: PMC12857768.
Gawrys O, Jíchová Š, Miklovič M, Husková Z, Kikerlová S, Sadowski J, Kollárová P, Lenčová-Popelova O, Hošková L, Imig JD, Mazurova Y, Kolář F, Melenovský V, Štěrba M, Červenka L. Characterization of a new model of chemotherapy-induced heart failure with reduced ejection fraction and nephrotic syndrome in Ren-2 transgenic rats. Hypertension research : official journal of the Japanese Society of Hypertension. 2024 Nov;47(11):3126-3146. doi: 10.1038/s41440-024-01865-7. PMID: 39245782; PMCID: PMC11534684.
Gomez F, Danos AM, Del Fiol G, Madabhushi A, Tiwari P, McMichael JF, Bakas S, Bian J, Davatzikos C, Fertig EJ, Kalpathy-Cramer J, Kenney J, Savova GK, Yetisgen M, Van Allen EM, Warner JL, Prior F, Griffith M, Griffith OL. A New Era of Data-Driven Cancer Research and Care: Opportunities and Challenges. Cancer discovery. 2024 Oct;14(10):1774-1778. doi: 10.1158/2159-8290.CD-24-1130. PMID: 39363742; PMCID: PMC11463721.
Corken AL, Ong V, Kore R, Ghanta SN, Karaduta O, Pathak R, Rose S, Porter C, Jain N. Platelets, inflammation, and purinergic receptors in chronic kidney disease. Kidney international. 2024 Sep;106(3):392-399. doi: 10.1016/j.kint.2024.03.033. PMID: 38821448; PMCID: PMC11343655.
Birrer M, Li G, Yunokawa M, Lee JY, Kim BG, Oppermann CP, Zhou Q, Nishio S, Okamoto A, Wu X, Mileshkin L, Oaknin A, Ray-Coquard I, Hasegawa K, Jehl G, Vugmeyster Y, Zhang S, Bajars M, Yonemori K. Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial. JAMA oncology. 2024 Sep;10(9):1204-1211. doi: 10.1001/jamaoncol.2024.2145. PMID: 39052242; PMCID: PMC11273284.
Went M, Duran-Lozano L, Halldorsson GH, Gunnell A, Ugidos-Damboriena N, Law P, Ekdahl L, Sud A, Thorleifsson G, Thodberg M, Olafsdottir T, Lamarca-Arrizabalaga A, Cafaro C, Niroula A, Ajore R, Lopez de Lapuente Portilla A, Ali Z, Pertesi M, Goldschmidt H, Stefansdottir L, Kristinsson SY, Stacey SN, Love TJ, Rognvaldsson S, Hajek R, Vodicka P, Pettersson-Kymmer U, Späth F, Schinke C, Van Rhee F, Sulem P, Ferkingstad E, Hjorleifsson Eldjarn G, Mellqvist UH, Jonsdottir I, Morgan G, Sonneveld P, Waage A, Weinhold N, Thomsen H, Försti A, Hansson M, Juul-Vangsted A, Thorsteinsdottir U, Hemminki K, Kaiser M, Rafnar T, Stefansson K, Houlston R, Nilsson B. Deciphering the genetics and mechanisms of predisposition to multiple myeloma. Nature communications. 2024 Aug;15(1):6644. doi: 10.1038/s41467-024-50932-7. PMID: 39103364; PMCID: PMC11300596.
Naqvi S, Shrestha A, Alzubi M, Alrawabdeh J, Thanendrarajan S, Zangari M, van Rhee F, Schinke C, Al Hadidi S. Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab. EJHaem. 2024 Aug;5(4):789-792. doi: 10.1002/jha2.971. PMID: 39157593; PMCID: PMC11327703.
Binz RL, Pathak R. G-Banding and Molecular Cytogenetics Detect Novel Translocations and Cryptic Aberrations in Human Immortal Endothelial Cells. International journal of molecular sciences. 2024 Jul;25(14). doi: 10.3390/ijms25147941. PMID: 39063182; PMCID: PMC11276908.
Li H, Mayr NA, Griffin RJ, Zhang H, Pokhrel D, Grams M, Penagaricano J, Chang S, Spraker MB, Kavanaugh J, Lin L, Sheikh K, Mossahebi S, Simone CB 2nd, Roberge D, Snider JW, Sabouri P, Molineu A, Xiao Y, Benedict SH. Overview and Recommendations for Prospective Multi-institutional Spatially Fractionated Radiation Therapy Clinical Trials. International journal of radiation oncology, biology, physics. 2024 Jul;119(3):737-749. doi: 10.1016/j.ijrobp.2023.12.013. PMID: 38110104; PMCID: PMC11162930.
Bustamante MS, Pierson SK, Ren Y, Bagg A, Brandstadter JD, Srkalovic G, Mango N, Alapat D, Lechowicz MJ, Li H, Van Rhee F, Lim MS, Fajgenbaum DC. Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease. Haematologica. 2024 Jul;109(7):2196-2206. doi: 10.3324/haematol.2023.283603. PMID: 38205523; PMCID: PMC11217716.
Shrestha A, Alzubi M, Alrawabdeh J, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Al Hadidi S. B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma. EJHaem. 2024 Jun;5(3):554-559. doi: 10.1002/jha2.896. PMID: 38895072; PMCID: PMC11182413.
Wright T, Turnis ME, Grace CR, Li X, Brakefield LA, Wang YD, Xu H, Kaminska E, Climer LK, Mukiza TO, Chang CL, Moldoveanu T, Opferman JT. Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1. Molecular cell. 2024 Apr;84(7):1338-1353.e8. doi: 10.1016/j.molcel.2024.02.035. PMID: 38503284; PMCID: PMC11017322.
Mao X, Yan W, Mery D, Liu J, Fan H, Xu J, Xu Y, Sui W, Deng S, Zou D, Du C, Yi S, van Rhee F, Barlogie B, Shaughnessy JD Jr, Anderson KC, Zhan F, Qiu L, An G. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. American journal of hematology. 2024 Apr;99(4):523-533. doi: 10.1002/ajh.27207. PMID: 38247315; PMCID: PMC10947864.
Rafae A, van Rhee F, Al Hadidi S. Perspectives on the Treatment of Multiple Myeloma. The oncologist. 2024 Mar;29(3):200-212. doi: 10.1093/oncolo/oyad306. PMID: 37995307; PMCID: PMC10911930.
Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D’Souza A, Chakraborty R, Mohan M, Schinke C. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024 Mar;109(3):906-914. doi: 10.3324/haematol.2023.283590. PMID: 37646658; PMCID: PMC10905074.
Aminov S, Giricz O, Melnekoff DT, Sica RA, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN, Parekh S, Verma A. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency. The Journal of clinical investigation. 2024 Feb;134(8). doi: 10.1172/JCI175199. PMID: 38376944; PMCID: PMC11014656.
Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Smith RT, Panozzo S, Alapat D MD, Cottler-Fox M, Tricot GJ, Shaughnessy JD Jr, Zhan F, Sawyer JR, Barlogie B, Zangari M, van Rhee F. Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood advances. 2024 Feb;8(3):703-707. doi: 10.1182/bloodadvances.2023011601. PMID: 38052037; PMCID: PMC10845028.
Hartupee C, Nagalo BM, Chabu CY, Tesfay MZ, Coleman-Barnett J, West JT, Moaven O. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Frontiers in immunology. 2024 Jan;15:1287459. doi: 10.3389/fimmu.2024.1287459. PMID: 38361931; PMCID: PMC10867137.
Shelton WJ, Zandpazandi S, Nix JS, Gokden M, Bauer M, Ryan KR, Wardell CP, Vaske OM, Rodriguez A. Long-read sequencing for brain tumors. Frontiers in oncology. 2024 Jan;14:1395985. doi: 10.3389/fonc.2024.1395985. PMID: 38915364; PMCID: PMC11194609.
Pierson SK, Lim MS, Srkalovic G, Brandstadter JD, Sarmiento Bustamante M, Shyamsundar S, Mango N, Lavery C, Austin B, Alapat D, Lechowicz MJ, Bagg A, Li H, Casper C, van Rhee F, Fajgenbaum DC. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes. Blood advances. 2023 Nov;7(21):6652-6664. doi: 10.1182/bloodadvances.2023010745. PMID: 37656441; PMCID: PMC10637880.
Shrum SA, Nukala U, Shrimali S, Pineda EN, Krager KJ, Thakkar S, Jones DE, Pathak R, Breen PJ, Aykin-Burns N, Compadre CM. Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects. Antioxidants (Basel, Switzerland). 2023 Nov;12(11). doi: 10.3390/antiox12111987. PMID: 38001840; PMCID: PMC10668991.
Kleman A, Singavi AK, Pommert L, Mathison AJ, Hari P, Dhakal B, Mohan M, Janz S, Knight JM, Shah MV, Schinke C, Burns RT, Steinhardt GF, Rao S, Carlson KB. A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy. Blood advances. 2023 Sep;7(18):5549-5553. doi: 10.1182/bloodadvances.2022008953. PMID: 36724511; PMCID: PMC10514068.
John L, Poos AM, Brobeil A, Schinke C, Huhn S, Prokoph N, Lutz R, Wagner B, Zangari M, Tirier SM, Mallm JP, Schumacher S, Vonficht D, Solé-Boldo L, Quick S, Steiger S, Przybilla MJ, Bauer K, Baumann A, Hemmer S, Rehnitz C, Lückerath C, Sachpekidis C, Mechtersheimer G, Haberkorn U, Dimitrakopoulou-Strauss A, Reichert P, Barlogie B, Müller-Tidow C, Goldschmidt H, Hillengass J, Rasche L, Haas SF, van Rhee F, Rippe K, Raab MS, Sauer S, Weinhold N. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nature communications. 2023 Aug;14(1):5011. doi: 10.1038/s41467-023-40584-4. PMID: 37591845; PMCID: PMC10435504.
Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, Van Rhee F, Al Hadidi SA. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood advances. 2023 Jul;7(13):3069-3074. doi: 10.1182/bloodadvances.2022009435. PMID: 36857755; PMCID: PMC10331406.
Nagalo BM, Zhou Y, Loeuillard EJ, Dumbauld C, Barro O, Elliott NM, Baker AT, Arora M, Bogenberger JM, Meurice N, Petit J, Uson PLS Jr, Aslam F, Raupach E, Gabere M, Basnakian A, Simoes CC, Cannon MJ, Post SR, Buetow K, Chamcheu JC, Barrett MT, Duda DG, Jacobs B, Vile R, Barry MA, Roberts LR, Ilyas S, Borad MJ. Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. Hepatology (Baltimore, Md.). 2023 Jun;77(6):1943-1957. doi: 10.1002/hep.32769. PMID: 36052732; PMCID: PMC12641542.
Nowak-Sliwinska P, van Beijnum JR, Griffioen CJ, Huinen ZR, Sopesens NG, Schulz R, Jenkins SV, Dings RPM, Groenendijk FH, Huijbers EJM, Thijssen VLJL, Jonasch E, Vyth-Dreese FA, Jordanova ES, Bex A, Bernards R, de Gruijl TD, Griffioen AW. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. Angiogenesis. 2023 May;26(2):279-293. doi: 10.1007/s10456-022-09863-4. PMID: 36459240; PMCID: PMC10119234.
Lowenthal R, Taylor M, Gidden JA, Heflin B, Lay JO Jr, Avaritt N, Tackett AJ, Urbaniak A. The mycelium of the Trametes versicolor synn. Coriolus versicolor (Turkey tail mushroom) exhibit anti-melanoma activity in vitro. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 May;161:114424. doi: 10.1016/j.biopha.2023.114424. PMID: 36827712; PMCID: PMC10147383.
Abu Za’nouneh FJ, Ababneh O, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD Jr, Zhan F, van Rhee F, Al Hadidi S. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023 May;4(2):454-458. doi: 10.1002/jha2.675. PMID: 37206288; PMCID: PMC10188470.
LaFargue CJ, Amero P, Noh K, Mangala LS, Wen Y, Bayraktar E, Umamaheswaran S, Stur E, Dasari SK, Ivan C, Pradeep S, Yoo W, Lu C, Jennings NB, Vathipadiekal V, Hu W, Chelariu-Raicu A, Ku Z, Deng H, Xiong W, Choi HJ, Hu M, Kiyama T, Mao CA, Ali-Fehmi R, Birrer MJ, Liu J, Zhang N, Lopez-Berestein G, de Franciscis V, An Z, Sood AK. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nature communications. 2023 Apr;14(1):2407. doi: 10.1038/s41467-023-36910-5. PMID: 37100807; PMCID: PMC10133315.
Osann K, Wenzel L, McKinney C, Wagner L, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Birrer M. Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors. Gynecologic oncology. 2023 Apr;171:151-158. doi: 10.1016/j.ygyno.2023.02.015. PMID: 36905875; PMCID: PMC10681156.
Penson RT, Ambrosio AJ, Whalen CA, Krasner CN, Konstantinopoulos PA, Bradley C, Matulonis UA, Birrer MJ. Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer. The oncologist. 2023 Mar;28(3):252-257. doi: 10.1093/oncolo/oyac275. PMID: 36718018; PMCID: PMC10020803.
Choudhury S, Byrum SD, Alkam D, Ashby C, Zhan F, Tackett AJ, Van Rhee F. Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics. Clinical epigenetics. 2023 Feb;15(1):18. doi: 10.1186/s13148-023-01433-9. PMID: 36737807; PMCID: PMC9898982.
Asfaw ZK, Rodriguez A, Hodges TR, Mazumdar M, Zhan S, Lim M, Germano IM. Diversity within the neurosurgical oncology workforce in the United States: A cross-sectional study with proposed strategies to pave the path forward. Neuro-oncology. 2023 Jan;25(1):177-184. doi: 10.1093/neuonc/noac150. PMID: 35705107; PMCID: PMC9825340.
Farley JH, Brady WE, O’Malley D, Fujiwara K, Yonemori K, Bonebrake A, Secord AA, Stephan JM, Walker JL, Nam JH, Birrer MJ, Gershenson DM. A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial. Gynecologic oncology. 2022 Dec;167(3):423-428. doi: 10.1016/j.ygyno.2022.10.006. PMID: 36244829; PMCID: PMC9789681.
Pierson SK, Katz L, Williams R, Mumau M, Gonzalez M, Guzman S, Rubenstein A, Oromendia AB, Beineke P, Fosså A, van Rhee F, Fajgenbaum DC. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nature communications. 2022 Nov;13(1):7236. doi: 10.1038/s41467-022-34873-7. PMID: 36433996; PMCID: PMC9700691.
Schinke C, Poos AM, Bauer MA, John L, Johnson SK, Deshpande S, Carrillo L, Alapat D, Rasche L, Thanendrarajan S, Zangari M, Al Hadidi S, van Rhee F, Davies FE, Raab MS, Morgan GJ, Weinhold N. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood advances. 2022 Nov;6(22):5873-5883. doi: 10.1182/bloodadvances.2022007217. PMID: 35977111; PMCID: PMC9647426.
Sekar G, Singh G, Qin X, Guibao CD, Schwam B, Inde Z, Grace CR, Zhang W, Slavish PJ, Lin W, Chen T, Lee RE, Rankovic Z, Sarosiek K, Moldoveanu T. Small molecule SJ572946 activates BAK to initiate apoptosis. iScience. 2022 Oct;25(10):105064. doi: 10.1016/j.isci.2022.105064. PMID: 36147946; PMCID: PMC9485059.
Stolarz AJ, Chhetri BP, Borrelli MJ, Jenkins SV, Jamshidi-Parsian A, Phillips JH, Fologea D, Gandy J, Griffin RJ. Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy. International journal of molecular sciences. 2022 Oct;23(19). doi: 10.3390/ijms231911662. PMID: 36232973; PMCID: PMC9569741.
van Rhee F, Rosenthal AL, Kanhai K, Martin RA, Nishimura KK, Hoering A, Fajgenbaum DC. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood advances. 2022 Aug;6(16):4773-4781. doi: 10.1182/bloodadvances.2022007112. PMID: 35793409; PMCID: PMC9631655.
Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, Poos AM, Zangari M, Thanendrarajan S, Davies FE, Walker BA, Barlogie B, Landgren O, Morgan GJ, van Rhee F, Weinhold N. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nature communications. 2022 Aug;13(1):4517. doi: 10.1038/s41467-022-32145-y. PMID: 35922426; PMCID: PMC9349320.
Brown CE, Rodriguez A, Palmer J, Ostberg JR, Naranjo A, Wagner J, Aguilar B, Starr R, Weng L, Synold TW, Tran V, Wang S, Reik A, D’Apuzzo M, Ressler JA, Zhou Y, Mendel M, Gregory PD, Holmes MC, Tang WW, Forman SJ, Jensen MC, Badie B. Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma. Neuro-oncology. 2022 Aug;24(8):1318-1330. doi: 10.1093/neuonc/noac024. PMID: 35100373; PMCID: PMC9340633.
Dweik A, Dweik H, Mian H, Mohan M, Schinke C, Al Hadidi S. Gender disparities in multiple myeloma publications. EJHaem. 2022 Aug;3(3):966-969. doi: 10.1002/jha2.470. PMID: 36051049; PMCID: PMC9422002.
Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J Jr, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA network open. 2022 Aug;5(8):e2228877. doi: 10.1001/jamanetworkopen.2022.28877. PMID: 36018590; PMCID: PMC9419017.
Fajgenbaum DC, Pierson SK, Kanhai K, Bagg A, Alapat D, Lim MS, Lechowicz MJ, Srkalovic G, Uldrick TS, van Rhee F. The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. British journal of haematology. 2022 Jul;198(2):307-316. doi: 10.1111/bjh.18214. PMID: 35507638; PMCID: PMC9544190.
Zhang Y, Blomquist TM, Kusko R, Stetson D, Zhang Z, Yin L, Sebra R, Gong B, Lococo JS, Mittal VK, Novoradovskaya N, Yeo JY, Dominiak N, Hipp J, Raymond A, Qiu F, Arib H, Smith ML, Brock JE, Farkas DH, Craig DJ, Crawford EL, Li D, Morrison T, Tom N, Xiao W, Yang M, Mason CE, Richmond TA, Jones W, Johann DJ Jr, Shi L, Tong W, Willey JC, Xu J. Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples. Genome biology. 2022 Jun;23(1):141. doi: 10.1186/s13059-022-02709-8. PMID: 35768876; PMCID: PMC9241261.
Li D, Yu X, Kottur J, Gong W, Zhang Z, Storey AJ, Tsai YH, Uryu H, Shen Y, Byrum SD, Edmondson RD, Mackintosh SG, Cai L, Liu Z, Aggarwal AK, Tackett AJ, Liu J, Wang GG. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. Oncogene. 2022 Jun;41(24):3328-3340. doi: 10.1038/s41388-022-02340-8. PMID: 35525905; PMCID: PMC9189076.
Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA network open. 2022 Apr;5(4):e228161. doi: 10.1001/jamanetworkopen.2022.8161. PMID: 35442451; PMCID: PMC9021907.
Xu C, Meng F, Park KS, Storey AJ, Gong W, Tsai YH, Gibson E, Byrum SD, Li D, Edmondson RD, Mackintosh SG, Vedadi M, Cai L, Tackett AJ, Kaniskan HÜ, Wang GG. A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells. Cell chemical biology. 2022 Mar;29(3):386-397.e9. doi: 10.1016/j.chembiol.2021.08.004. PMID: 34469831; PMCID: PMC8882712.
Larsen K, Spencer H, Mohan M, Bailey C, Hill K, Kottarathara M, Parikh R, Hoque S, Erra A, Mitma AA, Mathur P, Yarlagadda L, Gundarlapalli S, Ogunsesan Y, Hussain M, Thalambedu N, Sehti J, Al Hadidi S, Thanendrarajan S, Graziutti M, Zangari M, Barlogie B, van Rhee F, Tricot G, Schinke C. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of clinical medicine. 2022 Mar;11(6). doi: 10.3390/jcm11061640. PMID: 35329966; PMCID: PMC8955129.
Ntagwabira F, Trujillo M, McElroy T, Brown T, Simmons P, Sykes D, Allen AR. Piperlongumine as a Neuro-Protectant in Chemotherapy Induced Cognitive Impairment. International journal of molecular sciences. 2022 Feb;23(4). doi: 10.3390/ijms23042008. PMID: 35216124; PMCID: PMC8880369.
Mohan M, Kendrick S, Szabo A, Yarlagadda NK, Atwal D, Pandey Y, Roy AM, Parikh R, Lopez J, Thanendrarajan S, Schinke C, Alapat D, Sawyer JR, Tian E, Tricot G, van Rhee F, Zangari M. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood advances. 2022 Feb;6(3):808-817. doi: 10.1182/bloodadvances.2021005822. PMID: 34807986; PMCID: PMC8945288.
Corken A, Ghosh SP, Du R, Boerma M, Ware J, Pathak R. Platelet glycoprotein Ibα provides radiation protection. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2022 Feb;167:143-148. doi: 10.1016/j.radonc.2021.12.030. PMID: 34971661; PMCID: PMC8934272.
Zhang L, Moccia M, Briggs DC, Bharate JB, Lakkaniga NR, Knowles P, Yan W, Tran P, Kharbanda A, Wang X, Leung YK, Frett B, Santoro M, McDonald NQ, Carlomagno F, Li HY. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. Journal of medicinal chemistry. 2022 Jan;65(2):1536-1551. doi: 10.1021/acs.jmedchem.1c01280. PMID: 35081714; PMCID: PMC10536133.
Ajore R, Niroula A, Pertesi M, Cafaro C, Thodberg M, Went M, Bao EL, Duran-Lozano L, Lopez de Lapuente Portilla A, Olafsdottir T, Ugidos-Damboriena N, Magnusson O, Samur M, Lareau CA, Halldorsson GH, Thorleifsson G, Norddahl GL, Gunnarsdottir K, Försti A, Goldschmidt H, Hemminki K, van Rhee F, Kimber S, Sperling AS, Kaiser M, Anderson K, Jonsdottir I, Munshi N, Rafnar T, Waage A, Weinhold N, Thorsteinsdottir U, Sankaran VG, Stefansson K, Houlston R, Nilsson B. Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nature communications. 2022 Jan;13(1):151. doi: 10.1038/s41467-021-27666-x. PMID: 35013207; PMCID: PMC8748989.
Henriksen RA, Jenjaroenpun P, Sjøstrøm IB, Jensen KR, Prada-Luengo I, Wongsurawat T, Nookaew I, Regenberg B. Circular DNA in the human germline and its association with recombination. Molecular cell. 2022 Jan;82(1):209-217.e7. doi: 10.1016/j.molcel.2021.11.027. PMID: 34951964; PMCID: PMC10707452.
Pal S, Rahman J, Mu S, Rusch NJ, Stolarz AJ. Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies. Frontiers in pharmacology. 2022 Jan;13:850586. doi: 10.3389/fphar.2022.850586. PMID: 35308247; PMCID: PMC8930849.
Zhang Y, Gabere M, Taylor MA, Simoes CC, Dumbauld C, Barro O, Tesfay MZ, Graham AL, Ferdous KU, Savenka AV, Chamcheu JC, Washam CL, Alkam D, Gies A, Byrum SD, Conti M, Post SR, Kelly T, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM. Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Frontiers in oncology. 2022 Jan;12:1042250. doi: 10.3389/fonc.2022.1042250. PMID: 36457491; PMCID: PMC9706410.
Rossi JF, Chiang HC, Lu ZY, Levon K, van Rhee F, Kanhai K, Fajgenbaum DC, Klein B. Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling. Frontiers in immunology. 2022 Jan;13:919489. doi: 10.3389/fimmu.2022.919489. PMID: 35928820; PMCID: PMC9345304.
Zhang L, Lakkaniga NR, Bharate JB, Mcconnell N, Wang X, Kharbanda A, Leung YK, Frett B, Shah NP, Li HY. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. European journal of medicinal chemistry. 2021 Dec;225:113776. doi: 10.1016/j.ejmech.2021.113776. PMID: 34479037; PMCID: PMC8585723.
Reed MR, Lyle AG, De Loose A, Maddukuri L, Learned K, Beale HC, Kephart ET, Cheney A, van den Bout A, Lee MP, Hundley KN, Smith AM, DesRochers TM, Vibat CRT, Gokden M, Salama S, Wardell CP, Eoff RL, Vaske OM, Rodriguez A. A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma. Cells. 2021 Dec;10(12). doi: 10.3390/cells10123400. PMID: 34943910; PMCID: PMC8699481.
Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 Dec;106(12):3215-3218. doi: 10.3324/haematol.2021.278779. PMID: 34847659; PMCID: PMC8634177.
Kharbanda A, Zhang L, Saha D, Tran P, Xu K, Li MO, Leung YK, Frett B, Li HY. Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors. European journal of medicinal chemistry. 2021 Nov;223:113660. doi: 10.1016/j.ejmech.2021.113660. PMID: 34246853; PMCID: PMC9472513.
Darrigues E, Zhao EH, De Loose A, Lee MP, Borrelli MJ, Eoff RL, Galileo DS, Penthala NR, Crooks PA, Rodriguez A. Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion. International journal of molecular sciences. 2021 Oct;22(19). doi: 10.3390/ijms221910720. PMID: 34639060; PMCID: PMC8509225.
Mohan M, Maatman TC, Schinke C. The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma. Cancers. 2021 Sep;13(19). doi: 10.3390/cancers13194909. PMID: 34638393; PMCID: PMC8507719.
Deveson IW, Gong B, Lai K, LoCoco JS, Richmond TA, Schageman J, Zhang Z, Novoradovskaya N, Willey JC, Jones W, Kusko R, Chen G, Madala BS, Blackburn J, Stevanovski I, Bhandari A, Close D, Conroy J, Hubank M, Marella N, Mieczkowski PA, Qiu F, Sebra R, Stetson D, Sun L, Szankasi P, Tan H, Tang LY, Arib H, Best H, Burgher B, Bushel PR, Casey F, Cawley S, Chang CJ, Choi J, Dinis J, Duncan D, Eterovic AK, Feng L, Ghosal A, Giorda K, Glenn S, Happe S, Haseley N, Horvath K, Hung LY, Jarosz M, Kushwaha G, Li D, Li QZ, Li Z, Liu LC, Liu Z, Ma C, Mason CE, Megherbi DB, Morrison T, Pabón-Peña C, Pirooznia M, Proszek PZ, Raymond A, Rindler P, Ringler R, Scherer A, Shaknovich R, Shi T, Smith M, Song P, Strahl M, Thodima VJ, Tom N, Verma S, Wu L, Xiao W, Xu C, Yang M, Zhang G, Zhang S, Zhang Y, Shi L, Tong W, Johann DJ Jr, Mercer TR, Xu J, Johann Jr D. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nature biotechnology. 2021 Sep;39(9):1115-1128. doi: 10.1038/s41587-021-00857-z. PMID: 33846644; PMCID: PMC8434938.
Trujillo M, Kharbanda A, Corley C, Simmons P, Allen AR. Tocotrienols as an Anti-Breast Cancer Agent. Antioxidants (Basel, Switzerland). 2021 Aug;10(9). doi: 10.3390/antiox10091383. PMID: 34573015; PMCID: PMC8472290.
Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. Journal of medicinal chemistry. 2021 Aug;64(16):11747-11773. doi: 10.1021/acs.jmedchem.0c02167. PMID: 34402300; PMCID: PMC9697126.
Yarlagadda L, Boerma M, Gundarlapalli S, Parikh R, Landes RD, Kottarathara M, Ogunsesan Y, Hoque S, Mitma AA, Bailey C, Hill KM, Thanendrarajan S, Graziutti M, Mohan M, Zangari M, van Rhee F, Tricot G, Schinke C. Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers. 2021 Aug;13(16). doi: 10.3390/cancers13164019. PMID: 34439174; PMCID: PMC8392190.
Jenkins SV, Alimohammadi M, Terry AS, Griffin RJ, Tackett AJ, Leung JW, Vang KB, Byrum SD, Dings RPM. Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors. Angiogenesis. 2021 Aug;24(3):597-611. doi: 10.1007/s10456-021-09771-z. PMID: 33629198; PMCID: PMC8295215.
Ahn JH, Davis ES, Daugird TA, Zhao S, Quiroga IY, Uryu H, Li J, Storey AJ, Tsai YH, Keeley DP, Mackintosh SG, Edmondson RD, Byrum SD, Cai L, Tackett AJ, Zheng D, Legant WR, Phanstiel DH, Wang GG. Phase separation drives aberrant chromatin looping and cancer development. Nature. 2021 Jul;595(7868):591-595. doi: 10.1038/s41586-021-03662-5. PMID: 34163069; PMCID: PMC8647409.
Xu C, Tsai YH, Galbo PM, Gong W, Storey AJ, Xu Y, Byrum SD, Xu L, Whang YE, Parker JS, Mackintosh SG, Edmondson RD, Tackett AJ, Huang J, Zheng D, Earp HS, Wang GG, Cai L. Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer. Nucleic acids research. 2021 May;49(9):4971-4988. doi: 10.1093/nar/gkab252. PMID: 33849067; PMCID: PMC8136773.
Hamzah RN, Alghazali KM, Biris AS, Griffin RJ. Exosome Traceability and Cell Source Dependence on Composition and Cell-Cell Cross Talk. International journal of molecular sciences. 2021 May;22(10). doi: 10.3390/ijms22105346. PMID: 34069542; PMCID: PMC8161017.
Jones W, Gong B, Novoradovskaya N, Li D, Kusko R, Richmond TA, Johann DJ Jr, Bisgin H, Sahraeian SME, Bushel PR, Pirooznia M, Wilkins K, Chierici M, Bao W, Basehore LS, Lucas AB, Burgess D, Butler DJ, Cawley S, Chang CJ, Chen G, Chen T, Chen YC, Craig DJ, Del Pozo A, Foox J, Francescatto M, Fu Y, Furlanello C, Giorda K, Grist KP, Guan M, Hao Y, Happe S, Hariani G, Haseley N, Jasper J, Jurman G, Kreil DP, Łabaj P, Lai K, Li J, Li QZ, Li Y, Li Z, Liu Z, López MS, Miclaus K, Miller R, Mittal VK, Mohiyuddin M, Pabón-Peña C, Parsons BL, Qiu F, Scherer A, Shi T, Stiegelmeyer S, Suo C, Tom N, Wang D, Wen Z, Wu L, Xiao W, Xu C, Yu Y, Zhang Y, Zhang Z, Zheng Y, Mason CE, Willey JC, Tong W, Shi L, Xu J, Johann Jr D. A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency. Genome biology. 2021 Apr;22(1):111. doi: 10.1186/s13059-021-02316-z. PMID: 33863366; PMCID: PMC8051128.
Gong B, Li D, Kusko R, Novoradovskaya N, Zhang Y, Wang S, Pabón-Peña C, Zhang Z, Lai K, Cai W, LoCoco JS, Lader E, Richmond TA, Mittal VK, Liu LC, Johann DJ Jr, Willey JC, Bushel PR, Yu Y, Xu C, Chen G, Burgess D, Cawley S, Giorda K, Haseley N, Qiu F, Wilkins K, Arib H, Attwooll C, Babson K, Bao L, Bao W, Lucas AB, Best H, Bhandari A, Bisgin H, Blackburn J, Blomquist TM, Boardman L, Burgher B, Butler DJ, Chang CJ, Chaubey A, Chen T, Chierici M, Chin CR, Close D, Conroy J, Cooley Coleman J, Craig DJ, Crawford E, Del Pozo A, Deveson IW, Duncan D, Eterovic AK, Fan X, Foox J, Furlanello C, Ghosal A, Glenn S, Guan M, Haag C, Hang X, Happe S, Hennigan B, Hipp J, Hong H, Horvath K, Hu J, Hung LY, Jarosz M, Kerkhof J, Kipp B, Kreil DP, Łabaj P, Lapunzina P, Li P, Li QZ, Li W, Li Z, Liang Y, Liu S, Liu Z, Ma C, Marella N, Martín-Arenas R, Megherbi DB, Meng Q, Mieczkowski PA, Morrison T, Muzny D, Ning B, Parsons BL, Paweletz CP, Pirooznia M, Qu W, Raymond A, Rindler P, Ringler R, Sadikovic B, Scherer A, Schulze E, Sebra R, Shaknovich R, Shi Q, Shi T, Silla-Castro JC, Smith M, López MS, Song P, Stetson D, Strahl M, Stuart A, Supplee J, Szankasi P, Tan H, Tang LY, Tao Y, Thakkar S, Thierry-Mieg D, Thierry-Mieg J, Thodima VJ, Thomas D, Tichý B, Tom N, Garcia EV, Verma S, Walker K, Wang C, Wang Y, Wen Z, Wirta V, Wu L, Xiao C, Xiao W, Xu S, Yang M, Yip SH, Zhang G, Zhang S, Zhao M, Zheng Y, Zhou X, Mason CE, Mercer T, Tong W, Shi L, Jones W, Xu J, Johann Jr D. Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. Genome biology. 2021 Apr;22(1):109. doi: 10.1186/s13059-021-02315-0. PMID: 33863344; PMCID: PMC8051090.
Binz RL, Sadhukhan R, Miousse IR, Garg S, Koturbash I, Zhou D, Hauer-Jensen M, Pathak R. Dietary Methionine Deficiency Enhances Genetic Instability in Murine Immune Cells. International journal of molecular sciences. 2021 Feb;22(5). doi: 10.3390/ijms22052378. PMID: 33673497; PMCID: PMC7956689.
Li J, Galbo PM Jr, Gong W, Storey AJ, Tsai YH, Yu X, Ahn JH, Guo Y, Mackintosh SG, Edmondson RD, Byrum SD, Farrar JE, He S, Cai L, Tackett AJ, Zheng D, Wang GG. ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism. Nature communications. 2021 Feb;12(1):1045. doi: 10.1038/s41467-021-21357-3. PMID: 33594072; PMCID: PMC7886901.
Ewing LE, Skinner CM, Pathak R, Yee EU, Krager K, Gurley PC, Melnyk S, Boerma M, Hauer-Jensen M, Koturbash I. Dietary Methionine Supplementation Exacerbates Gastrointestinal Toxicity in a Mouse Model of Abdominal Irradiation. International journal of radiation oncology, biology, physics. 2021 Feb;109(2):581-593. doi: 10.1016/j.ijrobp.2020.09.042. PMID: 33002540; PMCID: PMC7855316.
Darrigues E, Elberson BW, De Loose A, Lee MP, Green E, Benton AM, Sink LG, Scott H, Gokden M, Day JD, Rodriguez A. Brain Tumor Biobank Development for Precision Medicine: Role of the Neurosurgeon. Frontiers in oncology. 2021 Jan;11:662260. doi: 10.3389/fonc.2021.662260. PMID: 33981610; PMCID: PMC8108694.
Van S, Pal S, Garner BR, Steed K, Sridharan V, Mu S, Rusch NJ, Stolarz AJ. Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation. Frontiers in pharmacology. 2021 Jan;12:727526. doi: 10.3389/fphar.2021.727526. PMID: 34483938; PMCID: PMC8415554.
Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, Sato Y, Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. American journal of hematology. 2020 Dec;95(12):1553-1561. doi: 10.1002/ajh.25992. PMID: 32894785; PMCID: PMC9547644.
Lakkaniga NR, Gunaganti N, Zhang L, Belachew B, Frett B, Leung YK, Li HY. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. European journal of medicinal chemistry. 2020 Nov;206:112691. doi: 10.1016/j.ejmech.2020.112691. PMID: 32823007; PMCID: PMC10536156.
Dhodapkar MV, Sexton R, Hoering A, Van Rhee F, Barlogie B, Orlowski R. Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Nov;26(22):5814-5819. doi: 10.1158/1078-0432.CCR-20-2119. PMID: 32816893; PMCID: PMC7679008.
Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF Jr, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nature medicine. 2020 Oct;26(10):1564-1568. doi: 10.1038/s41591-020-1060-8. PMID: 33020646; PMCID: PMC8063889.
Taylor EM, Byrum SD, Edmondson JL, Wardell CP, Griffin BG, Shalin SC, Gokden M, Makhoul I, Tackett AJ, Rodriguez A. Proteogenomic analysis of melanoma brain metastases from distinct anatomical sites identifies pathways of metastatic progression. Acta neuropathologica communications. 2020 Sep;8(1):157. doi: 10.1186/s40478-020-01029-x. PMID: 32891176; PMCID: PMC7487560.
Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A, Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, Lee Y, Nam DH, Kornblum HI, Wang M, Nakano I. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. The Journal of clinical investigation. 2020 Sep;130(9):5027. doi: 10.1172/JCI142404. PMID: 32870163; PMCID: PMC7456217.
Mason MJ, Schinke C, Eng CLP, Towfic F, Gruber F, Dervan A, White BS, Pratapa A, Guan Y, Chen H, Cui Y, Li B, Yu T, Chaibub Neto E, Mavrommatis K, Ortiz M, Lyzogubov V, Bisht K, Dai HY, Schmitz F, Flynt E, Dan Rozelle, Danziger SA, Ratushny A, Dalton WS, Goldschmidt H, Avet-Loiseau H, Samur M, Hayete B, Sonneveld P, Shain KH, Munshi N, Auclair D, Hose D, Morgan G, Trotter M, Bassett D, Goke J, Walker BA, Thakurta A, Guinney J. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020 Jul;34(7):1866-1874. doi: 10.1038/s41375-020-0742-z. PMID: 32060406; PMCID: PMC7326699.
Wongsurawat T, Jenjaroenpun P, De Loose A, Alkam D, Ussery DW, Nookaew I, Leung YK, Ho SM, Day JD, Rodriguez A. A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma. Acta neuropathologica communications. 2020 Jun;8(1):87. doi: 10.1186/s40478-020-00963-0. PMID: 32563269; PMCID: PMC7305623.
Schinke C, Boyle EM, Ashby C, Wang Y, Lyzogubov V, Wardell C, Qu P, Hoering A, Deshpande S, Ryan K, Thanendrarajan S, Mohan M, Yarlagadda N, Khan M, Choudhury SR, Zangari M, van Rhee F, Davies F, Barlogie B, Morgan G, Walker BA. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood cancer journal. 2020 Jun;10(6):70. doi: 10.1038/s41408-020-0336-z. PMID: 32555163; PMCID: PMC7303180.
McElroy T, Allen AR. A Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990-2019. Antioxidants (Basel, Switzerland). 2020 May;9(5). doi: 10.3390/antiox9050439. PMID: 32443630; PMCID: PMC7278845.
Moccia M, Frett B, Zhang L, Lakkaniga NR, Briggs DC, Chauhan R, Brescia A, Federico G, Yan W, Santoro M, McDonald NQ, Li HY, Carlomagno F. Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology. Journal of medicinal chemistry. 2020 May;63(9):4506-4516. doi: 10.1021/acs.jmedchem.9b01336. PMID: 32298114; PMCID: PMC7901654.